Pulse Biosciences (PLSE) EBITDA (2015 - 2025)

Pulse Biosciences' EBITDA history runs 11 years deep, the most recent figure standing at -$20.4 million for Q3 2025.

• On a quarterly basis, EBITDA fell 49.15% year-over-year to -$20.4 million in Q3 2025; TTM through Sep 2025 was -$78.9 million, a 62.68% decrease from a year earlier, with the FY2025 full-year figure at $194.0 million, up 444.93% from the prior year.
• EBITDA was little changed at -$20.4 million in Q3 2025 per PLSE's latest filing, from -$20.3 million in the prior quarter.
• Across five years, EBITDA topped out at -$8.7 million in Q4 2022 and bottomed at -$20.4 million in Q3 2025.
• The 5-year median for EBITDA is -$14.3 million (2021), against an average of -$14.7 million.
• Across the five-year window, EBITDA jumped 44.64% in 2023 and tumbled 72.91% in 2025, its largest moves.
• Year by year, EBITDA stood at -$15.4 million in 2021, then soared by 43.25% to -$8.7 million in 2022, then slumped by 43.32% to -$12.5 million in 2023, then tumbled by 61.66% to -$20.3 million in 2024, then retreated by 0.52% to -$20.4 million in 2025.
• Per Business Quant, the three latest PLSE EBITDA figures stand at -$20.4 million (Q3 2025), -$20.3 million (Q2 2025), and -$18.0 million (Q1 2025).